1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Posaconazole Injection Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 199 Wenhai North Road
         HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone: 908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview
Appearance: Aqueous solution
Colour: Colorless to pale yellow
Odour: Odourless

May cause an allergic skin reaction. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.

GHS Classification
Skin sensitisation: Category 1
Specific target organ toxicity - repeated exposure: Category 2
Short-term (acute) aquatic hazard: Category 3
Long-term (chronic) aquatic hazard: Category 3

GHS label elements
Hazard pictograms:

Signal word: Warning
Hazard statements: H317 May cause an allergic skin reaction.
H373 May cause damage to organs through prolonged or re-
Precautionary statements:

**Prevention:**
P260 Do not breathe mist or vapours.
P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves.

**Response:**
P302 + P352 IF ON SKIN: Wash with plenty of water.
P314 Get medical advice/attention if you feel unwell.
P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

**Disposal:**
P501 Dispose of contents/container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
May cause an allergic skin reaction. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards
Harmful to aquatic life. Harmful to aquatic life with long lasting effects.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts</td>
<td>182410-00-0</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Posaconazole</td>
<td></td>
<td>171228-49-2</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice:
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled:
If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact:
- In case of contact, immediately flush skin with soap and plenty of water.
- Remove contaminated clothing and shoes.
- Get medical attention.
- Wash clothing before reuse.
- Thoroughly clean shoes before reuse.

In case of eye contact:
- Flush eyes with water as a precaution.

If swallowed:
- If swallowed, DO NOT induce vomiting.
- Get medical attention.
- Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
- Diarrhoea
- Fever
- Headache
- Nausea
- Vomiting
- May cause an allergic skin reaction.
- May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders:
- First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
- Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

**Suitable extinguishing media**:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media**:
- None known.

**Specific hazards during firefighting**:
- Exposure to combustion products may be a hazard to health.

**Hazardous combustion products**:
- Carbon oxides
- Sulphur oxides
- Metal oxides

**Specific extinguishing methods**:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

**Special protective equipment for firefighters**:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
7. HANDLING AND STORAGE

Handling
Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage: Keep in properly labelled containers.
Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type</th>
<th>Control parameter</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Posaconazole Injection Formulation

<table>
<thead>
<tr>
<th>(Form of exposure)</th>
<th>ters / Permissible concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posaconazole 171228-49-2</td>
<td>TWA 300 µg/m³ (OEB 2) Internal</td>
</tr>
</tbody>
</table>

**Engineering measures**: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

**Personal protective equipment**
- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - **Filter type**: Particulates type
  - **Eye/face protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- **Skin and body protection**: Work uniform or laboratory coat.
- **Hand protection Material**: Chemical-resistant gloves
- **Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**9. PHYSICAL AND CHEMICAL PROPERTIES**
- **Appearance**: Aqueous solution
- **Colour**: Colorless to pale yellow
- **Odour**: odourless
- **Odour Threshold**: No data available
- **pH**: 2.6
- **Melting point/freezing point**: No data available
10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Posaconazole Injection Formulation

Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

.beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:
Acute oral toxicity: LD50 (Rat): > 8,800 mg/kg

Posaconazole:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 3,000 mg/kg
Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Posaconazole:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Posaconazole:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
May cause an allergic skin reaction.

Respiratory sensitisation
Not classified based on available information.
## Components:

### .beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:

**Assessment:** Probability or evidence of skin sensitisation in humans

### Posaconazole:

**Test Type:** Magnusson-Kligman-Test  
**Exposure routes:** Skin contact  
**Species:** Guinea pig  
**Result:** negative

### Germ cell mutagenicity

Not classified based on available information.

## Components:

### Posaconazole:

**Genotoxicity in vitro:**  
- **Test Type:** Bacterial reverse mutation assay (AMES)  
  - Result: negative  
  - Test Type: Chromosomal aberration  
  - Result: negative

**Genotoxicity in vivo:**  
- **Test Type:** Micronucleus test  
  - Species: Mouse  
  - Cell type: Bone marrow  
  - Application Route: Intravenous  
  - Result: negative

### Carcinogenicity

Not classified based on available information.

## Components:

### Posaconazole:

**Species:** Rat  
**Application Route:** oral (feed)  
**Exposure time:** 2 Years  
**Result:** positive  
**Remarks:** The mechanism or mode of action is not relevant in humans.

**Species:** Mouse  
**Application Route:** Oral  
**Exposure time:** 2 Years  
**Result:** positive  
**Remarks:** The mechanism or mode of action is not relevant in humans.

### Reproductive toxicity

Not classified based on available information.

## Components:

### .beta.-Cyclodextrin, sulfobutyl ethers, sodium salts:
### Posaconazole Injection Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>SDS Number</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.3</td>
<td>22497-00017</td>
<td>2020/10/01</td>
<td>2014/10/16</td>
</tr>
</tbody>
</table>

#### Effects on fertility

**Test Type:** Fertility  
**Species:** Rat  
**Application Route:** Intravenous injection  
**Result:** negative

#### Effects on foetal development

**Test Type:** Embryo-foetal development  
**Species:** Rat  
**Application Route:** Intravenous injection  
**Result:** negative

### Posaconazole:

#### Effects on fertility

**Test Type:** Fertility/early embryonic development  
**Species:** Rat, male  
**General Toxicity - Parent:** NOAEL: 180 mg/kg body weight  
**Symptoms:** No effects on mating performance  
**Result:** negative

**Test Type:** Fertility/early embryonic development  
**Species:** Rat, female  
**General Toxicity - Parent:** NOAEL: 45 mg/kg body weight  
**Symptoms:** No effects on mating performance  
**Result:** negative

#### Effects on foetal development

**Test Type:** Embryo-foetal development  
**Species:** Rat, female  
**Application Route:** Oral  
**Developmental Toxicity:** LOAEL: 29 mg/kg body weight  
**Result:** Fetotoxicity, Malformations were observed.

**Test Type:** Embryo-foetal development  
**Species:** Rabbit, female  
**Developmental Toxicity:** LOAEL: 40 mg/kg body weight  
**Result:** Fetotoxicity

#### Reproductive toxicity - Assessment

Some evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Posaconazole:

**Exposure routes:** Ingestion  
**Target Organs:** Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system  
**Assessment:** Causes damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

Components:

Posaconazole:
Species: Rat, female
LOAEL: 5 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species: Dog
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 392 Days
Target Organs: Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species: Monkey
LOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 1 Months
Target Organs: Bone marrow, Adrenal gland, Lymph nodes, Blood

Species: Dog
LOAEL: 3 mg/kg
Application Route: Oral
Exposure time: 56 Weeks
Target Organs: Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species: Monkey
LOAEL: 180 mg/kg
Application Route: Oral
Exposure time: 12 Months
Target Organs: Blood, Gastrointestinal tract, spleen

Species: Monkey
LOAEL: 8 mg/kg
Application Route: Intravenous
Exposure time: 1 Months
Target Organs: Cardio-vascular system, Lungs, Adrenal gland, Blood

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Posaconazole:
Ingestion: Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

\(\beta\)-Cyclodextrin, sulfobutyl ethers, sodium salts:

Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 220 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 96 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Selenastrum capricornutum (green algae)): > 100 mg/l
Exposure time: 72 h

Posaconazole:

Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.276 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity):

Toxicity to fish (Chronic toxicity):

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

M-Factor (Chronic aquatic toxicity):

Toxicity to microorganisms: EC50 (Natural microorganism): > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Persistence and degradability

Components:

Posaconazole:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 h
Method: OECD Test Guideline 314

Stability in water: Degradation half life (DT50): > 30 d
Method: OECD Test Guideline 111

Bioaccumulative potential

Components:

Posaconazole:
Bioaccumulation: Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 20
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 4.15

Mobility in soil

Components:

Posaconazole:
Distribution among environmental compartments: log Koc: 5.52

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Posaconazole Injection Formulation

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

GB 6944/12268
Not regulated as a dangerous good

Special precautions for user
Not applicable

15. REGULATORY INFORMATION

National regulatory information
Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

- AICS : not determined
- DSL : not determined
- IECSC : not determined

16. OTHER INFORMATION

Further information
Sources of key data used to compile the Safety Data Sheet

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Posaconazole Injection Formulation

Version 6.3  Revision Date: 2021/01/04  SDS Number: 22497-00017  Date of last issue: 2020/10/01

Date of first issue: 2014/10/16

1 organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN